Trial: 201903120

A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)

Phase

I

Principal Investigator

Tan, Benjamin

Disease Site

Liver

Learn more about this study at: clinicaltrials.gov